Devirs, cream 7.5% 15 g

Indications

As monotherapy or in combination with dosage forms of ribavirin for oral and parenteral use for the following diseases:
— infections of the skin and mucous membranes caused by Herpes simplex viruses types 1 and 2, of various localizations, incl. in the genital area;
— herpes zoster (as part of complex therapy).

Pharmacological effect

Pharmaceutical group:

Antiviral drug for external use

Pharmaceutical action:

Devirs is an antiviral drug.

Ribavirin triphosphate (RTP) is a potent inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase), viral RNA polymerase, and viral mRNA guanylyl transferase. Inhibition of the latter stops mRNA capping, which leads to a significant depletion of intracellular guanosine triphosphate reserves and inhibition of viral RNA and protein synthesis. Ribavirin is also incorporated into the viral genome, causing lethal mutations, with a subsequent decrease in the pathogenicity of the virus.

Ribavirin inhibits the replication of new virions, which reduces the viral load, and selectively inhibits viral RNA synthesis without suppressing RNA synthesis in normally functioning cells.

The most sensitive DNA viruses to ribavirin are herpes simplex virus, adenoviruses, CMV, smallpox viruses, Marek’s disease; RNA viruses – influenza A, B viruses, paramyxoviruses (parainfluenza, mumps, Newcastle disease), reoviruses, arenaviruses (Lassa fever virus, Bolivian hemorrhagic fever), bunyaviruses (Rift Valley fever virus, Crimean-Congo hemorrhagic fever virus), hantaviruses (hemorrhagic fever virus with renal or pulmonary syndrome), oncogenic RNA viruses.

DNA viruses insensitive to ribavirin: Varicella zoster, pseudorabies virus, vaccinia virus; RNA viruses: enteroviruses, rhinoviruses, Semliki forest encephalitis virus.

Pharmacokinetics:

When applied to the skin and topically, systemic absorption is minimal and practically negligible.

Special instructions

Do not use for the treatment of ophthalmoherpes, do not apply to the eye area.

The drug should be used with extreme caution in patients with renal failure.

Men and women of childbearing age should use effective contraception during treatment and for 7 months after the end of therapy.

Active ingredient

Ribavirin

Composition

Active substance:

ribavirin 7.5 g

Excipients:

glyceryl monostearate (glycerol monostearate 40-45) – 2.0 g,

macrogol 6 cetostearyl alcohol ether (macrogol 6 cetostearyl ether) – 1.5 g, macrogol 25 cetostearyl alcohol ether (macrogol 25 cetostearyl ether) – 1.5 g,

cetostearyl alcohol – 5.0 g,

liquid paraffin (vaseline oil) – 5.0 g,

methyl parahydroxybenzoate (methylhydroxybenzoate, methylparaben, nipagin) – 0.1 g,

propyl parahydroxybenzoate (propylhydroxybenzoate, propylparaben, nipazole) – 0.02 g,

purified water – up to 100.0 g.

Contraindications

— pregnancy;
– period of lactation (breastfeeding);
– children and adolescents up to 18 years of age;
– hypersensitivity to the components of the drug Devirs.
With caution. The drug Devirspry should be used for renal failure in men and women of reproductive age.

Side Effects

Allergic reactions are possible (skin rash, urticaria, exanthema).

Other: hair loss, changes in thyroid-stimulating hormone (TSH), symptoms of autoimmune diseases (extremely rare).
The observed effects are usually reversible, do not affect the effectiveness of treatment and cease after completion of treatment.

Storage conditions

In a dry place, at a temperature not exceeding 25 °C

Shelf life

2 years

Manufacturer

Vertex, Russia